Because of its pre-eminent research powerhouses, Carnegie Mellon University and the University of Pittsburgh, the region distinguishes itself in biotech. And wherever distinctive competencies exist, investment should occur. Likewise, where the opportunity for return is high, the investment should be equally high. It's that simple. By this measure, biotech also merits substantial investment.
Return is generally a function of risk.
Biotech investments are more risky, so they must bear more potential to be attractive to investors. The total investment to date in biotech here has not yet reflected the potential that Kirkpatrick and others like her see. The initial lack of local investor understanding didn't deter her. A Saskatchewan, Canada, native, Kirkpatrick was attracted to Pittsburgh because of the academic and research prowess available here. Also, one of the initial partners in ProlX was a Pittsburgher.